Medicare Advantage plans have been cleared to seek cheaper alternatives for biologicals beginning next year.
As drug prices climb, is it time to ask whether the landmark technology transfer law is a fair deal for US taxpayers?
Regulatory intervention having limited impact on fostering innovation.
Will US right-to-try legislation be a means of giving hope to terminally ill patients, or drug another way for drug regulatory standards to fall?
Competitive bidding, an attempt to bring down Medicare costs, might lead to higher out-of-pocket costs for patients.
The US government is trying to change the way Medicare reimburses doctors for office-administered drugs – but whether it will succeed is another story.
Unitary patents are important for the biopharma sector, but might be even more crucial for medtech.
How the EMA's move out of London could impact European drug approvals.